peripheral arterial disease

in review 6 min read Updated 2026-10-19
PAD is a marker of systemic atherothrombosis: MACE risk dominates, limb loss is the minority outcome. Diagnose with ABI <0.9 (TBI when ABI >1.4 from calcified vessels). Symptomatic PAD → rivaroxaban 2.5 mg BID + ASA if bleeding risk is low (especially with high-risk limb or comorbidity), otherwise single antiplatelet (clopidogrel preferred, weak). Asymptomatic PAD → no antithrombotic for the limb, no revascularisation. Every patient: smoking cessation, maximally tolerated statin with add-on to threshold, ACEi/ARB for hypertension, SGLT2i if diabetic, supervised walking for claudication. No screening for CAD or carotid disease.

antithrombotic choice

PAD occlusions are largely thrombotic, not just plaque progression (“athero-thrombo-embolism”) → dual pathway inhibition (low-dose factor Xa inhibitor + platelet inhibitor) reduces both MACE and limb events where antiplatelets alone fall short.

flowchart TD
    A[Lower extremity PAD] --> B{Symptomatic or prior revascularisation/amputation?}
    B -- No: isolated asymptomatic --> C[No antithrombotic for PAD<br/>treat CAD/stroke indications if present]
    B -- Yes --> D{Needs full-dose OAC for AF/VTE?}
    D -- Yes --> E[OAC alone<br/>add antiplatelet only if coronary or peripheral event &lt;1 year]
    D -- No --> F{Bleeding risk}
    F -- High --> G[SAPT: clopidogrel 75 mg, weak preference, or ASA]
    F -- Low --> H{High-risk limb or comorbidity?}
    H -- Yes --> I[Rivaroxaban 2.5 mg BID + ASA 80–100 mg]
    H -- No --> J[Rivaroxaban 2.5 mg BID + ASA, or SAPT<br/>shared decision]
    I -. rivaroxaban contraindicated .-> K[DAPT: ASA + clopidogrel or ticagrelor]
  • High-risk limb: prior revascularisation, amputation, rest pain, ischaemic ulcer. High-risk comorbidity: polyvascular disease, diabetes, HF, renal insufficiency
  • Benefit scales with risk: in COMPASS PAD subgroups, MACE + MALE ARR 4.4–5.2% with high-risk limb or comorbidity vs ≈1% with neither; major bleeding ARI <1%
  • Rivaroxaban 2.5 mg BID avoid: strong CYP3A4/P-gp interactors, stroke <1 month, any prior haemorrhagic stroke, eGFR <15. Severe HF (NYHA III–IV, LVEF <30%) was excluded from COMPASS but use is reasonable if otherwise indicated
  • Rivaroxaban 2.5 mg BID is not anticoagulation for AF or VTE
  • Full-dose OAC added to antiplatelet for stable PAD → no limb or MACE benefit, ~3.4× life-threatening bleeding (WAVE (2007)) → recommended against
  • Clopidogrel over ASA as SAPT is a weak CCS recommendation, from the PAD subgroup of CAPRIE (1996); Thrombosis Canada treats ASA 81 mg as standard and clopidogrel as the alternative (ASA intolerance, possibly slightly better). Ticagrelor no better than clopidogrel in PAD (EUCLID (2017))
  • Recent coronary revascularisation (<1 year) → antiplatelet regimen per ACS/PCI guidance → post-MI care; AF + vascular disease → antithrombotic therapy in AF with CAD

after revascularisation

settingregimen
elective endovascularrivaroxaban 2.5 mg BID + ASA 80–100 mg (strong); ± clopidogrel ≤30 days for complex stenting
elective open (bypass)rivaroxaban 2.5 mg BID + ASA 80–100 mg (strong)
endovascular, rivaroxaban not possibleDAPT (ASA + clopidogrel) ≥1 month (CCS; Thrombosis Canada 1–3 months)
open, rivaroxaban not possibleSAPT or VKA; VKA favoured for high-risk autologous vein grafts (poor/long conduit, poor runoff, prior failed bypass)
urgent/emergent (acute limb ischaemia)any of: full-dose OAC + SAPT, rivaroxaban 2.5 mg BID + ASA ± short clopidogrel, or DAPT (weak). High re-thrombosis + low bleeding risk → OAC + SAPT
  • VOYAGER PAD (2020): rivaroxaban + ASA vs ASA after revascularisation → MACE + MALE HR 0.85, driven by ↓acute limb ischaemia; ↑ISTH major bleeding, no excess ICH or fatal bleeding. Clopidogrel >30 days → ↑major bleeding
  • Continue rivaroxaban + ASA long term after revascularisation (prior revascularisation = high-risk limb)
  • Periprocedural: hold rivaroxaban 2.5 mg 12–24 h; clopidogrel 5–7 days; ASA continued for low-bleeding-risk procedures → periprocedural anticoagulation

diagnosis

  • Classic claudication (exertional calf cramp, reproducible distance, relieved within 10 min of rest) in only 5–10% of PAD; most are atypical or asymptomatic
  • Differential: spinal stenosis, neuropathy, radiculopathy, hip/knee arthritis, Baker cyst, chronic compartment syndrome, venous claudication, popliteal entrapment
  • CLTI: ischaemic rest pain, ulcer or gangrene. 1-year mortality ≈22% and major amputation ≈22% without revascularisation

ABI and TBI

ABI = higher ankle systolic pressure (DP or PT) ÷ higher brachial systolic pressure, per leg.

resultmeaning
ABI <0.9PAD (sens ≈61%, spec ≈92%)
ABI >1.4non-compressible (medial calcification: diabetes, CKD, age) → unreliable → TBI, tibial waveforms ± TcPO₂
TBI <0.6PAD (digital arteries usually spared from calcification)
  • Symptomatic → confirm with ABI and/or TBI (strong)
  • Asymptomatic >50 with risk factors (smoking, diabetes) → ABI screening suggested (weak); no population-wide screening (strong, against)
  • Patients with PAD → no routine screening for asymptomatic CAD or carotid stenosis (weak, against): management is identical whichever bed is diseased
  • Arm-to-arm BP difference → use the higher arm for BP management

risk factor management

targetrecommendation
smokingcessation (strong): counselling + varenicline, combination NRT, bupropion; e-cigarettes in selected patients. Ask at every visit
lipidsstatin-indicated by definition → max tolerated statin; add ezetimibe and/or PCSK9i if LDL ≥1.8, non-HDL ≥2.4 or apoB ≥0.7 g/L (strong). PCSK9i first if far above threshold. TG 1.5–5.6 on statin → icosapent ethyl → dyslipidaemia
BPACEi or ARB first line (strong). Targets → hypertension. Caution if SBP <110 (↑MACE and MALE). Beta-blockers not contraindicated
diabetesSGLT2i (strong) — no amputation signal with empagliflozin or dapagliflozin; canagliflozin signal unresolved → SGLT2 inhibitors. GLP-1 RA or DPP-4i reasonable (weak). Tight glycaemic control: weak evidence

claudication and revascularisation

  • Supervised exercise first line (strong): walking preferred; ≥2 sessions/week of ≥30 min for ≥12 weeks; walk to moderate–severe claudication (3–4/5), rest, repeat. Home/community structured programme if supervised unavailable (strong). Then walk ≥30 min ≥3×/week to maintain benefit
  • Cilostazol unavailable in Canada; pentoxifylline, carnitine and chelation not recommended
  • Claudication natural history: 2–3%/year progress to CLTI, amputation ≤1%/year → revascularisation only for lifestyle-limiting symptoms after failed exercise + OMT, with acceptable risk (weak). Early intervention does not change natural history
  • Asymptomatic PAD → no revascularisation (strong)
  • CLTI → urgent vascular surgery referral (strong); debride/minor amputation first if deep infection or wet gangrene; primary major amputation if non-reconstructable, non-ambulatory, sepsis or short life expectancy
  • Acute limb ischaemia → emergent IV heparin + vascular surgery; exclude cardioembolic source to set long-term antithrombotic
favours endovascularfavours open
focal aortoiliac or femoropopliteal diseasediffuse aortoiliac or infrainguinal disease
claudication indicationcommon femoral or profunda disease (endarterectomy)
no adequate vein, prohibitive surgical riskadequate vein conduit
expected survival <2 yearssurvival >2 years, failed endovascular
  • Bypass: autologous vein over prosthetic (strong); no femoral–tibial bypass for claudication (strong, against)
  • No endovascular therapy in the common femoral or profunda (strong, against) → endarterectomy or hybrid

pre-op risk for vascular surgery

  • RCRI underestimates MACE in vascular surgery → not recommended (strong, against). Use VSG-CRI or INFRA VQI-CRI for cardiac risk, frailty (mFI ≥0.25 or functional dependence) for 30-day mortality
  • Pre-op BNP or NT-proBNP suggested (weak). NT-proBNP ≥300 ng/L or BNP ≥92 ng/L → ≈22% 30-day death/MI → consider post-op monitoring
  • Emergency revascularisation is not delayed for risk assessment

Prepared 2026-10-19. Not yet verified — check every number against the sources.

Key references

+3 more sources

Suggest a correction peripheral arterial disease